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Abstract
The discovery of activating mutations in BRAF at high frequency in cutaneous melanoma opened 
the door to new treatment options, which have resulted in significantly better patient outcomes. 
Treatments such as the FDA-approved RAF inhibitor vemurafenib, and the more recently 
approved dabrafenib and trametinib combination therapy are designed to target the ERK1/2 
pathway. Initial success in targeting this pathway is evidenced by the high percentage of 
melanoma patients who undergo tumor remission. However, the beneficial effects of these 
targeted therapies are usually short-lived due to the development of resistance, which leads to 
disease progression. As a result, studies have focused on the acquired forms of resistance that 
develop following continued exposure to therapy. Conversely, far fewer studies have investigated 
the adaptive forms of resistance, which activate rapidly, promote cell survival and may underlie 
the development of acquired resistance by providing melanoma cells the time to develop 
additional mutations. We provide a detailed review of the known mechanisms of adaptive 
resistance in melanoma and relate them to similar responses to targeted therapies in other tumor 
types.
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Introduction
The development of selective RAF inhibitors, such as vemurafenib and dabrafenib, has 
revolutionized the treatment of melanoma patients harboring v-raf murine sarcoma viral 
oncogene homolog B1 (BRAF) V600E mutations. Despite this major breakthrough, the 
clinical response of patients to these targeted inhibitors is extremely heterogeneous. In the 
phase II trial for vemurafenib (ClinicalTrials.gov number, NCT00949702), 6% of patients 
displayed a complete response, 47% of patients were partial responders, and 14% progressed 
Corresponding Authors: Curtis H. Kugel III (Curtis.Kugel@Jefferson.edu) and Andrew E. Aplin (Andrew.Aplin@Jefferson.edu). 
Disclosure of Potential Conflicts of Interest: The authors declare they have no competing financial relationships.
NIH Public Access
Author Manuscript
Pigment Cell Melanoma Res. Author manuscript; available in PMC 2015 November 01.
Published in final edited form as:
Pigment Cell Melanoma Res. 2014 November ; 27(6): 1032–1038. doi:10.1111/pcmr.12264.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
with no tumor shrinkage (Sosman et al., 2012). A variable response was also observed in the 
combination therapy phase II trial of the RAF inhibitor dabrafenib plus the mitogen-
activated protein kinase kinase (MEK) inhibitor trametinib (ClinicalTrials.gov number, 
NCT01072175), although the waterfall plot is shifted towards more partial and complete 
responses (Flaherty et al., 2012). Given the need to predict effective responders, it becomes 
critical to understand the mechanisms that underlie this heterogeneous response to RAF and 
MEK inhibitors in order to identify biomarkers that can predict objective responses versus 
primary resistance in BRAF V600E melanoma patients. We believe that adaptive responses 
to RAF inhibitors in BRAF V600E melanoma are a major determinant of the susceptibility 
of a tumor to targeted therapy.
Adaptive responses versus acquired resistance
It is important to differentiate between the different modes of resistance to targeted 
inhibitors, particularly, between adaptive responses and acquired resistance. We describe 
adaptive responses as mechanisms that are switched on to compensate for actions of BRAF 
and MEK inhibition in BRAF V600E melanoma cells. These responses are rapid, occurring 
within hours of drug treatment, and reversible in that drug removal resets the compensatory 
signal to its basal state. We postulate that when adaptive responses are exhibited by the 
majority of cells within the tumor, the degree of tumor shrinkage will be limited. At an 
individual cell level, adaptive responses promote survival signals that afford the cell time 
until a bona fide acquired mechanism takes over that allows permanent survival and growth 
in the presence of inhibitor. Acquired resistance at the level of the tumor refers to lesions 
that dramatically shrink with RAF inhibitors but subsequently regrow, often at a rapid rate. 
Outgrowth of cells may be due to the acquisition of a secondary mutation and/or selection of 
a single cell or small population of cells that harbor a pre-existing genetic alteration that 
negates the effect of RAF inhibitors. Alterations underlying acquired resistance are stable 
changes that allow irreversible resistance and often even a growth advantage that is drug 
dependent (Das Thakur et al., 2013; Hartsough et al., 2014).
In this review, we focus on mechanisms of adaptive response to RAF and MEK inhibitors. 
We divide these mechanisms into three broad modes: re-setting of extracellular signal-
regulated kinase (ERK1/2) pathway activation, up-regulation of receptor tyrosine kinases 
(RTK) leading to compensatory PI-3K-AKT activation, and changes in metabolic pathways 
(see Figure 1). For mechanisms of acquired resistance to BRAF inhibitors, we point readers 
to several recent reviews, which have comprehensively covered this subject (Hartsough et 
al., 2013; Salama and Flaherty, 2013).
Re-setting of ERK1/2 pathway activation
Mutant BRAF is a potent activator of MEK-ERK1/2 signaling (Davies et al., 2002) and 
RAF inhibitors efficiently reduce signaling through this pathway. Although often depicted in 
a simplified linear RAS-RAF-MEK-ERK1/2 model, signaling through this pathway is 
modulated at multiple levels. Scaffold molecules including kinase suppressor of RAS (KSR) 
(Morrison, 2001), MEK partner 1 (MP1), and IQ-motif GTPase-activating protein (IQGAP), 
have been described to control activation at distinct steps in the pathway and/or at 
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subcellular locales (Kolch, 2005). Furthermore, the pathway is finely tuned through the 
action of negative feedback regulators such as Sprouty (SPRY) and Spred proteins which act 
at the level of RTK-RAS-RAF signaling (Kim and Bar-Sagi, 2004), and dual-specificity 
phosphatases (DUSPs) that dephosphorylate the activation loop of ERK1/2 (Owens and 
Keyse, 2007). In summary, these feedback regulators are responsible for dampening 
ERK1/2 pathway output.
Reactivation of the ERK1/2 pathway through stable events such as expression of 
neuroblastoma RAS viral oncogene homolog (NRAS) Q61 mutants or BRAF V600E splice 
variants is a common occurrence in acquired resistance to RAF inhibitors in melanoma 
(Nazarian et al., 2010; Poulikakos et al., 2011). Work from the Rosen laboratory indicates 
that re-setting of ERK1/2 pathway activity also contributes to the initial adaptive response to 
RAF inhibitors. In microarray studies, Sproutys, SPRY2 and SPRY4, and DUSPs 4 and 6 
were identified to be significantly down-regulated by BRAF or MEK inhibition in cultured 
BRAF V600E melanoma cells (Pratilas et al., 2009). Active, GTP-loaded RAS is often very 
low when BRAF V600E is expressed but the loss of SPRY2 expression following 
vemurafenib treatment correlates with an increase in RAS activation (Lito et al., 2012). In 
turn, RAS activation enhances signaling through the ERK1/2 pathway in a manner 
dependent on BRAF/v-Raf-1 murine leukemia viral oncogene homolog 1 (CRAF) 
heterodimers (Lito et al., 2012; Heidorn et al., 2010). It is worth noting that ERK1/2 
reactivation occurred in only a subset of the lines tested and was modest in that it did not 
rebound close to levels associated with full activity (Corcoran et al., 2012; Lito et al., 2012). 
Conversely, similar studies in BRAF V600E colorectal cancer and thyroid carcinoma cell 
lines showed robust ERK1/2 reactivation in comparison to BRAF V600E melanomas 
(Corcoran et al., 2012; Montero-Conde et al., 2013), suggesting that the level of ERK1/2 
pathway reactivation differs between lineages and contributes in a significant manner to the 
poor response of mutant BRAF colorectal cancer and thyroid carcinoma patients to 
vemurafenib (Montero-Conde et al., 2013). Nonetheless, it is likely that even low level 
ERK1/2 re-activation and pathway output will contribute to the initial response of melanoma 
to RAF inhibitors. Targeting MEK downstream of BRAF/CRAF heterodimers using 
PD0325901 subsequent to RAF inhibitor treatment reduced ERK1/2 rebound and 
simultaneous treatment of tumor xenografts with both RAF and MEK inhibitors led to more 
pronounced tumor growth inhibition than either treatment alone (Lito et al., 2012). These 
data are consistent with the phase I/II results from the recently FDA-approved combination 
therapy of dabrafenib and trametinib in which progression-free survival and response rates 
were improved to 9.4 months and 76% respectively with the combination therapy compared 
to 5.8 months and 54% with dabrafenib monotherapy (Flaherty et al., 2012).
Collectively, these findings emphasize that multiple levels of fine-tuning are associated with 
the ERK1/2 pathway. Adaptive resetting of ERK1/2 flux occurs in some mutant BRAF 
melanoma lines following RAF inhibition due to the reduction of negative feedback 
regulators. Combinatorial targeting of RAF and MEK lessens ERK1/2 reactivation in cell-
based studies and increases both the rate and duration of responses in patients.
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Adaptive up-regulation of RTKs leading to activation of alternative 
signaling pathways
Early studies on resistance to vemurafenib in BRAF V600E melanomas indicated the 
involvement of the RTKs platelet-derived growth factor receptor (PDGFR) and insulin-like 
growth factor receptor (IGF-1R) (Nazarian et al., 2010; Villanueva et al., 2010). While these 
studies focused on mechanisms of acquired resistance, there is increasing evidence for up-
regulation of RTKs as a rapid adaptive response to RAF inhibitors in BRAF V600E 
melanomas.
Upregulation of v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3 (ERBB3)/
human epidermal growth factor receptor 3 (HER3) signaling is one example of an adaptive 
response to BRAF V600E inhibition. ERBB3 is a member of the epidermal growth factor 
receptor (EGFR)/ERBB family of RTKs (Wilson et al., 2009) but is not well studied 
compared to other family members. Initial studies showed that the forkhead box 
transcription factor D3 (FOXD3) is up-regulated following inhibition of the BRAF V600E-
MEK-ERK1/2 pathway and modulates the survival of mutant BRAF melanoma cells in 
response to RAF inhibitors (Basile et al., 2012). Expression microarrays and chromatin 
immunoprecipitation coupled to DNA sequencing (ChIP-seq) analyses on FOXD3 target 
genes identified ERBB3 as being upregulated in cells overexpressing FOXD3 or treated 
with RAF inhibitors (Abel et al., 2013). ERBB3 expression was upregulated rapidly (within 
4-6 hours) following exposure of cultured BRAF V600E/D melanoma cells to vemurafenib 
and was dependent on FOXD3 (Abel et al., 2013). ERBB3 upregulation was associated with 
enhanced sensitivity to its ligand, neuregulin-1 beta (NRG1), as determined by increased 
ERBB3 phosphorylation on carboxyl-terminal tyrosine residues upon treatment with 
exogenous NRG1. Effects were reversible, as removal of vemurafenib reset cells to a state 
displaying reduced response to NRG1. It is likely that NRG1 is produced mainly by cells in 
the tumor microenvironment since basal ERBB3 phosphorylation is low in cell 
monocultures in vitro, but is readily detectable in intradermal xenografts of mutant BRAF 
melanoma cells in vivo (Abel et al., 2013) and when cells are stimulated by conditioned 
medium from dermal fibroblasts (unpublished data). Studies with patient samples from RAF 
inhibitor trials supported the clinical relevance of these findings since ERBB3 
phosphorylation was significantly higher in on-treatment samples compared to matched pre-
treatment samples (Abel et al., 2013).
Cytoplasmic tyrosine phosphorylation of ERBB3 creates high affinity binding sites for the 
Src-homology 2 (SH2) domain of the catalytic subunit of phosphatidylinositol 3-kinase 
(PI-3K). In turn, PI-3K signals through the phosphoinositide-dependent kinase 1-v-akt 
murine thymoma viral oncogene (AKT) pathway, which is known to protect against the 
apoptotic actions of RAF inhibitors (Shao and Aplin, 2010; Paraiso et al., 2011; Gopal et al., 
2010). Notably, ERBB3 differs from the other members of the family in that it exhibits very 
low kinase activity (Wilson et al., 2009; Shi et al., 2010). Thus, ERBB3 partners with its 
family member, v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2 (ERBB2), 
to elicit downstream signaling. NRG1-activated ERBB3-ERBB2 complexes led to enhanced 
growth, proliferation, and viability of RAF- or MEK-inhibited mutant BRAF melanoma 
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cells in vitro. Conversely, vemurafenib combined with ERBB3 depletion or the ERBB2/
EGFR inhibitor, lapatanib, to reduce the beneficial effects of NRG1 treatment in multiple 
BRAF V600E cell lines in vitro and enhanced effects of PLX4720 (the tool compound for 
vemurafenib) to significantly reduce tumor growth in vivo (Abel et al., 2013). The 
generation and utility of humanized neutralizing anti-ERBB3 antibodies is currently 
garnering much interest from the pharmaceutical industry (Gala and Chandarlapaty, 2014). 
Work currently in submission from our group shows that targeting ERBB3 with neutralizing 
antibodies in combination with PLX4720 can reduce tumor growth and promote durable 
responses in vivo (Kugel et al., manuscript under review). Thus, targeting ERBB3 may 
increase the efficacy of RAF inhibitors.
Although originally implicated in acquired resistance, platelet-derived growth factor 
receptor (PDGFRβ) is also upregulated as an adaptive response to RAF inhibition. 
Treatment of mutant BRAF melanoma cells with either vemurafenib, MEK inhibitor 
(AZD6244) or ERK1/2 inhibitor (FR180204) resulted in increased AKT phosphorylation 
(Shi et al., 2013). Use of the PDGFRβ inhibitor, sunitinib, indicated that AKT activation was 
attributed, in part, to the upregulation of PDGFRβ, although sunitinib did not fully inhibit 
the adaptive increase in AKT activation resulting from vemurafenib treatment. The 
combination of sunitinib and the EGFR inhibitor, gefitinib, resulted in maximal AKT 
inhibition, although EGFR expression is typically low in BRAF V600E melanoma 
(Corcoran et al., 2012; Prahallad et al., 2012). However, the Bernards group described a 
resistance mechanism to RAF inhibition whereby a subset of cells with elevated expression 
of EGFR displayed slow growth properties in the absence of inhibitor but were selected for 
in the presence of vemurafenib. Immunohistochemistry on patient samples confirmed 
elevated levels of EGFR in a percentage of patients who relapsed while on RAF and/or 
MEK inhibitor therapy (Sun et al., 2014). The slow growth phenotype of EGFR high-
expressing cells suggests that patients displaying elevated EGFR following relapse to 
ERK1/2 pathway inhibitors would benefit from a “drug holiday” (Sharma et al., 2010). This 
work describes a mechanism in which the tumor as a whole may “adapt” to ERK1/2 
inhibition. However, since the subset of cells express high levels of EGFR prior to RAF 
inhibition, at the cellular level we view this mechanism as a selection of a population with 
pre-existing resistance. Overall, these findings suggest that multiple RTKs may contribute to 
the response to RAF inhibitors in BRAF V600E melanomas and promote initial tumor 
survival.
The diversity of receptors that play a role in adaptive responses to RAF inhibition highlights 
the need to identify biomarkers that may serve as predictors for combinatorial targeting of 
RTKs and the ERK1/2 pathway. As the RTKs presented here predominantly activate the 
pro-survival PI-3K-AKT pathway, targeting this pathway may be a viable option to 
overcome RTK activity. However, while the AKT inhibitor MK2206 in combination with 
vemurafenib (Shi et al., 2013) and previous work showing PI-3K inhibitor in combination 
with a MEK inhibitor (Smalley et al., 2006) decreased colony growth in vitro compared to 
treatment with either alone, the utilization of PI-3K and AKT inhibitors in patients has been 
limited by toxicities (Curry et al., 2013). Furthermore, experience from other tumor types 
indicates that the efficiency of PI-3K and AKT inhibitors may be hampered by upregulation 
of RTKs as a compensatory effect (see below).
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Adaptive RTK upregulation in response to targeted therapies in non-
melanoma tumor types
BRAF mutations are also found in various tumor types besides melanoma. Although 
approximately 10% of colorectal cancers harbor BRAF V600E perturbations (Davies et al., 
2002), vemurafenib is clinically ineffective in these patients compared to effects observed in 
melanoma (Kopetz et al., 2010). In vitro studies demonstrate that the resistance of BRAF 
V600E colorectal cancer cell lines is associated with an adaptive mechanism that utilizes 
intrinsically high levels of phosphorylated EGFR to engage signaling machinery to activate 
RAS and, consequently, reactivate the ERK1/2 pathway (Corcoran et al., 2012; Prahallad et 
al., 2012). A secondary mechanism may also be present that leads to an adaptive increase in 
IGF1R signaling to AKT (Corcoran et al., 2012). Regulation downstream of the receptor is 
similar to the notion of feedback mechanisms described by Rosen and colleagues in 
melanoma. In contrast to colorectal cancer cells, mutant BRAF melanoma cells often have 
low EGFR expression by utilization of other RTKs for adaptive responses in this tumor type. 
Additionally, BRAF V600E mutations are found in approximately 30% of papillary thyroid 
carcinomas and, when treated with vemurafenib, these cancers display increased expression 
and phosphorylation of ERBB3 (Montero-Conde et al., 2013).
Interestingly, adaptive response mechanisms have also been identified following treatment 
of non-mutant BRAF tumor types with targeted agents other than RAF inhibitors. In 
ERBB2-amplified breast cancer lines treated with ERBB family tyrosine kinase inhibitors, 
PI-3K inhibitors and/or AKT inhibitors, there is an induction of multiple phosphorylated 
RTKs with increased ERBB3 expression/phosphorylation being most notable 
(Chandarlapaty et al., 2011; Chakrabarty et al., 2012; Sergina et al., 2007; Serra et al., 
2011). Importantly, upregulation of ERBB3 is detected in samples from patients treated with 
the AKT inhibitor GDC-0068 (ClinicalTrials.gov: NCT01090960), demonstrating that 
compensatory mechanisms occur in a clinical setting (Yan et al., 2013). These adaptive 
responses may be regulated by the tumor microenvironment. Muranen et al. showed that 
ovarian and breast cells adherent to the basement membrane extracellular matrix (ECM) 
displayed resistance to a dual specificity PI-3K/mTOR inhibitor in a 3D spheroid model 
(Muranen et al., 2012). This apparent ECM-mediated protection was associated with an 
adaptive signaling program involving multiple RTKs (EGFR, ERBB2 and IGF-1R), 
alternative signaling pathways (phosphorylation of STAT3 and STAT6) and pro-survival 
proteins (e.g. Bcl-2). Targeting several of these nodes, specifically EGFR, IGF-1R and 
Bcl-2, prevented resistance to PI-3K/mTOR inhibitors. Thus, these studies show that 
adaptive responses modulated by the tumor microenvironment will likely limit the efficacy 
of PI-3K and AKT inhibitors.
Oxidative metabolic responses
Oxidative phosphorylation, the primary metabolic process in normal human cells, provides a 
high yield of ATP compared to the alternative metabolic process of glycolysis (Papa et al., 
2012). It is now widely accepted that the majority of cancers undergo a metabolic switch, 
known as the Warburg effect, in which glycolysis is favored over oxidative phosphorylation 
(Warburg, 1956). The reason for this switch is not completely understood; however, it is not 
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due to loss of oxidative phosphorylation function (Moreno-Sánchez et al., 2007). Recently, 
an adaptive response to RAF inhibition was identified involving a metabolic reprogramming 
of mutant BRAF melanoma cells to revert back to oxidative phosphorylation and promote 
the survival of cells in the presence of drug (Haq et al., 2013). Gene set enrichment analysis 
(GSEA) on published patient data identified oxidative phosphorylation and ATP synthesis 
signatures that were increased in patients treated with vemurafenib. Notably, ERK1/2 
pathway inhibition increased mRNA levels of the transcriptional coactivator peroxisome 
proliferator-activated receptor gamma coactivator 1 alpha (PGC1α). This finding was 
unique to melanomas and was directly controlled by up-regulation of microphthalmia-
associated transcription factor (MITF). Overexpression of MITF in cells resulted in a 
reduction in lactate production, suggesting a decrease in glycolysis. Conversely, knockdown 
of MITF in patient-derived cell lines led to a significant enrichment of oxidative 
phosphorylation genes, which are regulated by PGC1α. These data suggest that inhibition of 
the ERK1/2 pathway in melanoma cells relieves suppression of MITF and PGC1α, which in 
turn, controls expression of oxidative phosphorylation genes. Notably, high PGC1α levels 
correlated with poor prognosis in patients (Haq et al., 2013). Reduced sensitivity to pathway 
inhibition by increased oxidative phosphorylation is mediated by an increase in both 
mitochondrial number and function. Furthermore, mitochondrial uncouplers and oxidative 
phosphorylation inhibitors combined with RAF inhibitor to decrease cell viability.
In a separate mechanism, activation of the oxidative phosphorylation pathway was also 
found in slow-cycling mutant BRAF cells that survived vemurafenib treatment. Levels of 
the H3K4-demethylase, lysine-specific demethylase 5B (JARID1B), were rapidly increased 
(within 72 hours) in response to the DNA damaging therapeutic cisplatin or by vemurafenib 
treatment of mutant BRAF cells in vitro and in xenografts. Increased JARID1B expression 
was also detected in samples from patients who relapsed while on vemurafenib compared to 
their matched pre-treatment controls. Knockdown of JARID1B combined with vemurafenib 
to reduce tumor growth in mice harboring BRAF V600E melanoma cell xenografts. 
Quantitative proteome profiling identified an increase in proteins associated with oxidative 
phosphorylation in cells over-expressing JARID1B. Similar to the findings of Haq et al., the 
oxidative phosphorylation inhibitor, oligomycin, combined with vemurafenib treatment to 
reduce colony growth in vitro and tumor xenograft growth of mutant BRAF cells. 
Interestingly, this effect was not dependent on ERK1/2 pathway targeting agents, as the 
emergence of cells with high JARID1B levels occurred in response to various 
chemotherapeutics (Roesch et al., 2013). Increased histone demethylase function, 
specifically that of JARID1A, has been previously implicated in a subpopulation of the 
EGFR mutant non-small cell lung cancer cells that are resistant to the EGFR inhibitor 
gefitinib; however, in that study, resistance was not attributed to an increase in oxidative 
phosphorylation but rather IGF1R-dependent signaling (Sharma et al., 2010).
Collectively, these studies describe a metabolic re-programming of mutant BRAF cells in 
response to targeted inhibitors as well as standard therapeutics. These findings suggest the 
potential benefit of targeting oxidative phosphorylation in combination with RAF inhibitors; 
however, such drugs have toxicity concerns in the clinic (Dykens and Will, 2007) and 
further refinement is likely to be required before combinatorial treatment is practical.
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Conclusions
While the number of effective treatment options for metastatic melanoma has increased 
dramatically in the last three years, these treatments have revealed multiple resistance 
mechanisms such as resetting of the ERK1/2 pathway, RTK-mediated AKT activation, and 
deregulation of metabolic processes, which invariably lead to tumor regrowth. The 
heterogeneity of these mechanisms highlight the potential issue that within a single patient 
and possibly within a single tumor, multiple adaptive responses will present a complicated 
and difficult barrier. The identification and targeting of adaptive response mechanisms 
presented here may provide at least a partial solution to this problem. Combinatorial 
targeting of the ERK1/2 pathway and adaptive responses may increase the efficacy of 
current therapeutics by reducing the number of cells that survive initial drug treatment. This 
in turn will lower the percentage of surviving cells capable of acquiring additional mutations 
and is expected to decrease the likelihood of acquired resistance and disease progression. 
This indicates a strong need for the identification of biomarkers indicative of adaptive 
mechanisms in order to develop combinatorial treatments to enhance current targeted 
therapy treatments in mutant BRAF metastatic melanoma patients.
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Figure 1. Overview of the adaptive mechanisms to RAF inhibitors in mutant BRAF melanoma
(Left) ERK1/2 pathway inhibition by vemurafenib leads to downregulation of DUSP and 
SPRY proteins. Loss of SPRY results in more efficient NRAS activation leading to a 
reactivation of the ERK1/2 pathway. This is enhanced by reduced ERK1/2 
dephosphorylation resulting from lower levels of DUSP proteins. (Middle) Vemurafenib 
treatment increases PDGFRβ and ERBB3 leading to activation of the AKT pathway and 
promoting resistance to ERK1/2 pathway inhibition. (Right) Increased levels of JARID1B 
and PGC1α following ERK1/2 pathway inhibition leads to a metabolic switch from 
glycolysis to oxidative phosphorylation promoting resistance to RAF inhibition. 
Abbreviations used are: EGFR, epidermal growth factor receptor; GRB2, growth factor 
receptor-bound protein 2; SOS, son of sevenless; NRAS, neuroblastoma RAS viral 
oncogene homolog; BRAF, v-Raf murine sarcoma viral oncogene homolog B1; CRAF, v-
Raf-1 murine leukemia viral oncogene homolog 1; MEK, mitogen-activated protein kinase 
kinase; ERK, extracellular signal-regulated kinase; DUSP, dual-specificity phosphatase; 
SPRY, sprouty; PDGFRβ, platelet-derived growth factor receptor, beta polypeptide; 
ERBB3, v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3; ERBB2, v-erb-
b2 avian erythroblastic leukemia viral oncogene homolog 2; PI-3K, phosphatidylinositol 3-
kinase; AKT, v-akt murine thymoma viral oncogene; FOXD3, forkhead box transcription 
factor D3; JARID1B, lysine-specific demethylase 5B; MITF, microphthalmia-associated 
transcription factor; PGC1α, peroxisome proliferator-activated receptor gamma coactivator 
1 alpha.
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